Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227


A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor.

Boran AD, Seco J, Jayaraman V, Jayaraman G, Zhao S, Reddy S, Chen Y, Iyengar R.

PLoS One. 2012;7(11):e49702. doi: 10.1371/journal.pone.0049702.


Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.

Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F.

Lung Cancer. 2011 Mar;71(3):283-90. doi: 10.1016/j.lungcan.2010.06.005.


Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer.

Wang J, Barnes RO, West NR, Olson M, Chu JE, Watson PH.

Breast Cancer Res. 2008;10(3):R51. doi: 10.1186/bcr2105.


Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.

BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188.


Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.

Iwase M, Takaoka S, Uchida M, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M.

Oral Oncol. 2008 Apr;44(4):361-8.


Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.

Clin Cancer Res. 2006 Jan 15;12(2):617-25.


EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.

Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R, He J.

Amino Acids. 2012 Nov;43(5):2027-35. doi: 10.1007/s00726-012-1277-z.


Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.

Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M.

Clin Cancer Res. 2009 Jun 1;15(11):3697-704. doi: 10.1158/1078-0432.CCR-08-2042.


Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.


The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.


AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, Zuo J, Jiang H, Geng M, Ding J.

PLoS One. 2011;6(7):e21487. doi: 10.1371/journal.pone.0021487.


Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.

Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K, Harada M, Nakano S.

J Cell Biochem. 2006 Mar 1;97(4):724-34.


Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.

Zhang YW, Jiang XX, Chen QS, Shi WY, Wang L, Sun HD, Shen ZX, Chen Z, Chen SJ, Zhao WL.

Exp Hematol. 2010 Mar;38(3):191-201. doi: 10.1016/j.exphem.2009.12.005.


Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.

Lee DH, Szczepanski MJ, Lee YJ.

J Cell Biochem. 2009 Apr 15;106(6):1113-22. doi: 10.1002/jcb.22098.


ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.

Nautiyal J, Yu Y, Aboukameel A, Kanwar SS, Das JK, Du J, Patel BB, Sarkar FH, Rishi AK, Mohammad RM, Majumdar AP.

Mol Cancer Ther. 2010 Jun;9(6):1503-14. doi: 10.1158/1535-7163.MCT-10-0019. Erratum in: Mol Cancer Ther. 2010 Sep;9(9):2637.

Supplemental Content

Support Center